One-Stop Solutions for Biotechnology
SHANGHAIJune 15, 2026 /PRNewswire/ — At the start of the “15th Five-Year Plan” period, with biomedicine positioned as an emerging pillar industry, Festo is making its debut at CPHI & PMEC China 2026 by synergizing its Life Sciences and Process Automation business units. Under the theme “From Lab Automation to Mass Production: Festo Provides One-Stop Solutions for Biotechnology,” the company focuses on core topics such as process scale-up, commercial production, and compliant digitalization, showcasing its overall strength in the pharmaceutical industry (Booth: W5 Hall, F06).
One-Stop Solutions for Full-Chain Integration from “Lab” to “Industrialization”
Against the backdrop of the biomedical industry’s accelerated shift toward process transformation and intelligent upgrades, seamless transition from R&D to mass production is critical. Festo’s first exhibition demonstrates its complete end-to-end capabilities spanning “lab automation” and “mass production.”
Benchtop Glass Bioreactor Solution: Designed for stringent cell culture conditions, this intelligent system, built with VEMD mass flow controllers, VEAE valve manifolds, and EMMT/CMMT servo combinations, enables precise regulation of multiple gases such as air and oxygen. Leveraging high-performance servo control technology, it delivers exceptional synchronization and tracking accuracy, ensuring optimal cell growth environments. It is widely applicable to product manufacturing using synthetic biology, genetically engineered recombinant proteins, DNA vaccines, 3D tissue cell culture, and amplification of microbial cell factories in critical bioprocesses.
Lab Liquid Dispensing Device: This system features a syringe pump driven by an ultra-low-voltage, dynamically excited permanent magnet synchronous servo motor (EMMT-EC) and a high-precision ball screw actuator, paired with a high-performance 3/2 VYKA media valve for high-speed, high-accuracy aspiration and dispensing. The device supports ultra-fast switching (3–5 ms) with zero dead volume, setting a new technical benchmark for high-throughput drug screening and precision dispensing.
Industrial-Grade Bioreactor: Festo showcases its core control solution for industrial-grade bioreactors. Leveraging advanced technologies in gas handling, liquid handling, and control systems, this solution addresses process pain points in large-scale fermentation and cultivation, such as batch failures due to improper control, providing highly reliable stability for biological drug substance preparation.
Explosion-Proof Valve Terminal Cabinet: Addressing stringent safety requirements in industrial mass production, traditional solutions involving extensive cable laying, wiring, commissioning, and later troubleshooting incur high overall costs. In contrast, Festo’s explosion-proof valve terminal cabinet reduces on-site hard wiring through bus communication, lowering material usage and wiring complexity. The cabinet can be integrated and tested at the factory, reducing on-site installation, wiring, and commissioning efforts, thereby improving project delivery efficiency. Additionally, for explosion-proof zones such as Zone 1 and Zone 2, Festo’s explosion-proof valve terminal cabinet offers comprehensive explosion-proof certification solutions, configurable with increased safety or intrinsic safety designs as needed. These solutions have been widely applied in industries such as chemicals, pharmaceuticals, and food, accumulating extensive field experience and project cases to support users in safety, reliability, and maintenance convenience.
Through this series of exhibits covering everything from lab pre-processing to factory-scale mass production, Festo aims to help customers overcome pain points such as time-consuming manual operations, error-proneness, and insufficient precision, significantly enhancing experimental efficiency and minimizing the risk of batch failures during process transfer.
New Regulations Drive Data Integrity and Full Lifecycle Management
Currently, regulatory policies in the biopharmaceutical industry are tightening. China’s new version of the “Good Manufacturing Practice for Medical Devices” will take effect on November 1, 2026. The new regulations impose unprecedented requirements for “data integrity” during production processes and “full lifecycle management” of equipment.
In this industry trend, Festo’s AI software, Festo AX, emerges as a powerful tool to help enterprises overcome compliance challenges and achieve intelligent transformation. The software enables real-time predictive maintenance, quality analysis, and energy monitoring for pharmaceutical equipment. More importantly, it ensures transparent data flow and automated recording throughout the production process, perfectly aligning with the new regulations’ requirements for data traceability and integrity. On-site, two exhibits equipped with digital diagramming software FluidDraw and predictive maintenance software MIE create an immersive digital experience zone, demonstrating how AI can drive intelligent upgrades across the entire production process.
Additionally, leveraging three Life Sciences Application Centers in the United States, Germany, and China, when medical device manufacturers need to establish stricter supplier management systems, Festo’s professional technical engineering team provides one-stop services from feasibility studies, parameter optimization, and prototype construction to commissioning and installation, helping customers meet the stringent supply chain requirements of the new regulations. By building a full value chain system centered on “technological innovation, quality production, and value-added services,” Festo responds to customers’ growing personalized needs and higher demands for product lifecycle management.
Reference Images:
Benchtop Glass Bioreactor
Lab Liquid Dispensing Device
Industrial-Grade Bioreactor
Explosion-Proof Valve Terminal Cabinet